Right ON target: a new RAS-GTP inhibitor
D Senft - Nature Reviews Cancer, 2024 - nature.com
Right ON target: a new RAS-GTP inhibitor | Nature Reviews Cancer Skip to main content Thank
you for visiting nature.com. You are using a browser version with limited support for CSS. To …
you for visiting nature.com. You are using a browser version with limited support for CSS. To …
Anticancer drugs: How to select small molecule combinations?
R Nussinov, BR Yavuz, H Jang - Trends in Pharmacological Sciences, 2024 - cell.com
Small molecules are at the forefront of anticancer therapies. Successive treatments with
single molecules incur drug resistance, calling for combination. Here, we explore the tough …
single molecules incur drug resistance, calling for combination. Here, we explore the tough …
Finding the sweet spot: Targeting RAS in tumors while sparing normal tissue
N Perurena, K Cichowski - Cancer Cell, 2024 - cell.com
The development of mutant-selective KRAS inhibitors represents a major therapeutic
advance; however, patients can develop resistance through feedback mechanisms and …
advance; however, patients can develop resistance through feedback mechanisms and …
HRS-4642: The next piece of the puzzle to keep KRAS in check
AA Flores-Gómez, M Drosten - Cancer Cell, 2024 - Elsevier
KRAS G12D is the most frequent KRAS mutation in human cancer. In this issue, Zhou et al.
describe a novel KRAS G12D inhibitor, HRS-4642, that shows potent and selective anti …
describe a novel KRAS G12D inhibitor, HRS-4642, that shows potent and selective anti …
Resistance to KRAS inhibition in stage IV lung cancer
KB Sreter, MJ Catarata, M von Laffert, A Frille - Frontiers in Oncology, 2024 - frontiersin.org
Lung cancer remains the leading cause of cancer death globally. More than 50% of new
cases are diagnosed in an advanced or metastatic stage, thus contributing to the poor …
cases are diagnosed in an advanced or metastatic stage, thus contributing to the poor …
[HTML][HTML] Critical Appraisal and Future Challenges of Artificial Intelligence and Anticancer Drug Development
E Chamorey, J Gal, B Mograbi, G Milano - Pharmaceuticals, 2024 - mdpi.com
The conventional rules for anti-cancer drug development are no longer sufficient given the
relatively limited number of patients available for therapeutic trials. It is thus a real challenge …
relatively limited number of patients available for therapeutic trials. It is thus a real challenge …
Exploring and clinical validation of prognostic significance and therapeutic implications of copper homeostasis-related gene dysregulation in acute myeloid leukemia
M Abulimiti, Z Jia, Y Wu, J Yu, Y Gong, N Guan… - Annals of …, 2024 - Springer
The patterns and biological functions of copper homeostasis-related genes (CHRGs) in
acute myeloid leukemia (AML) remain unclear. We explored the patterns and biological …
acute myeloid leukemia (AML) remain unclear. We explored the patterns and biological …